Prevention and management of CMV infection in pediatric solid organ transplant recipients

• Published in: Frontiers in pediatrics Vol. 11; p. 1098434
• Main Authors: Balani, Shanthi S., Sadiq, Sanober, Jensen, Chelsey J., Kizilbash, Sarah J.
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 20.02.2023
• Subjects: cytomegalovirus emerging treatment; cytomegalovirus prevention; cytomegalovirus treatment; opportunistic infections; pediatric solid organ transplant; Pediatrics; cytomegalovirus prevention; cytomegalovirus treatment; opportunistic infections; cytomegalovirus emerging treatment; pediatric solid organ transplant
• ISSN: 2296-2360; 2296-2360
• DOI: 10.3389/fped.2023.1098434

Human cytomegalovirus (CMV) remains one of the most common opportunistic infections following solid organ transplantation in children. CMV causes morbidity and mortality through direct tissue-invasive disease and indirect immunomodulatory effects. In recent years, several new agents have emerged for the prevention and treatment of CMV disease in solid organ transplant recipients. However, pediatric data remain scarce, and many of the treatments are extrapolated from the adult literature. Controversies exist about the type and duration of prophylactic therapies and the optimal dosing of antiviral agents. This review provides an up-to-date overview of treatment modalities used to prevent and treat CMV disease in solid organ transplant (SOT) recipients.